



Anti-microbial Perspective of a Chalcone, (*E*)-1-(1-methoxy-9*H*-carbazol-3-yl)-3-(4-(methylsulfonyl)phenyl)prop-2-en-1-one: Fabrication of a Hybrid by Unification of a Natural Product with a Synthetic Component

 Debarshi Kar Mahapatra ^{1*}, Ruchi S. Shivhare ²

To cite this article : Mahapatra, D. K., & Shivhare, R. S. (2018). Anti-microbial Perspective of a Chalcone, (*E*)-1-(1-methoxy-9*H*-carbazol-3-yl)-3-(4-(methylsulfonyl) phenyl)prop-2-en-1-one: Fabrication of a Hybrid by Unification of a Natural Product with a Synthetic Component. Int J Agr Life Sci, 4(2), 236-240. doi: 10.22573/spg.ijals.018.s12200090

To link to this article : <https://doi.org/10.22573/spg.ijals.018.s12200090>

Copyright : © 2018 Mahapatra, D. K et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the Original work is properly cited.

Data Availability Statement : All relevant data are within the paper and its Supporting Information files.

Funding : The author(s) received no specific funding for this work.

Competing Interests : The authors have declared that no competing interests exist.




© 2018 The Author(s). Published by Skyfox Publishing Group



Published online: 30 June 2018.




Submit your article to this journal 



View CrossMark data



View related articles 



RESEARCH ARTICLE

Anti-microbial Perspective of a Chalcone, (*E*)-1-(1-methoxy-9*H*-carbazol-3-yl)-3-(4-(methylsulfonyl)phenyl)prop-2-en-1-one: Fabrication of a Hybrid by Unification of a Natural Product with a Synthetic Component

Debarshi Kar Mahapatra ^{1*}, Ruchi S. Shivhare ²

1. Department of Pharmaceutical Chemistry, Dadasaheb Balpande College of Pharmacy, Nagpur 440037, Maharashtra, India
2. Department of Pharmaceutical Chemistry, Kamla Nehru College of Pharmacy, Nagpur 441108, Maharashtra, India

*Author to whom correspondence should be addressed; E-Mail: dkmbsp@gmail.com

Received: May 2018 / Accepted: June 2018/ Published: June 2018

ABSTRACT: *Murraya koenigii* L. has been explored exhaustively and is known to possess more than 20 different carbazole-based alkaloids having multifarious therapeutic perception of this class of alkaloids, murrayanine is the highest explored alkaloid and is known to have (ethno)-pharmacological perspectives of purgative, astringent, febrifuge, anti-helminthic, anti-oxidant, anti-ulcerogenic, immunomodulation, etc. As murrayanine possess multiple sites for substituting wide-range of electron-donating / -withdrawing groups by semi-synthetic approach, in the present research, a chalcone; (*E*)-1-(1-methoxy-9*H*-carbazol-3-yl)-3-(4-(methylsulfonyl)phenyl)prop-2-en-1-one was fabricated rationally by incorporating a natural portion (murrayanine) in the A-ring and a synthetic component (4-methylsulfonyl group) in the B-ring and screened against two bacterial species (*Escherichia coli* and *Staphylococcus aureus*) and two fungal species (*Candida albicans* and *Aspergillus niger*). The rationally designed chalcone demonstrated noteworthy anti-microbial activity. The fabricated chalcone was observed to be a better anti-bacterial agent as compared to its anti-fungal potentials. As compared to the standard drugs, the experimental molecule does hold well against pathogenic challenges. The present research therefore opened new avenues of judiciously developing a natural scaffold having an active methylsulfonyl group, which will inspire life science researchers across the globe in developing inhibitors with pronounced biological activity as compared with the parent compounds.

Keywords: *Murraya koenigii*, murrayanine, chalcone, methylsulfonyl, antimicrobial, antibacterial

INTRODUCTION

Murrayanine is a natural product obtained from *Murraya koenigii* L. (Rutaceae) (Mahapatra *et al.*, 2018). It is a carbazole alkaloid known to have (ethno)-pharmacological perspectives of purgative, astringent, febrifuge, anti-helminthic, anti-oxidant, anti-ulcerogenic, immunomodulation, etc (Mahapatra *et al.*, 2018a). *Murraya koenigii* L. has been explored exhaustively and is known to possess more than 20 different carbazole-based alkaloids having multifarious therapeutic perception (Shivhare *et al.*, 2016) of this class of alkaloids, murrayanine is the highest explored and utilized component that finds its imperative role in the pharmacotherapeutics owing to diverse attributes like multiple sites for substituting wide-range of electron-donating / -withdrawing groups by semi-synthetic approaches, simple chemistry, and several other key factors (Mahapatra *et al.*, 2018b). Over the years, a number of heterocyclic hybrids have been reported by our research group. Murrayanine based therapeutically active heterocycles like oxazole, pyrimidine, thiazole, pyrazole, hydantoin, thiadiazole, phthalimide, isoxazole, benzodiazepine, benzoxazepine, and benzothiazepine have been fabricated which demonstrated tremendous potentials (Mahapatra *et al.*, 2018c; Mahapatra *et al.*, 2018d; Mahapatra *et al.*, 2017; Mahapatra *et al.*, 2017a; Mahapatra *et al.*, 2017b; Mahapatra *et al.*, 2017c).

Similarly, an effort has been made in rational designing of a natural scaffold "chalcone" by unifying the natural product 'murrayanine' with a synthetic component '4-methylsulfonyl'. Thereby, combining a natural portion with a synthetic part to yield a component which itself is of a natural constitution (Figure 1). In the majority of the cases, it has been observed that substituting an active synthetic group often enhances the biological activity (Mahapatra *et al.*, 2017d). In the upcoming research, several hybrids of natural products are evidenced which have demonstrated superior activity than the parent moieties from which they have derived (Mahapatra *et al.*, 2017e). The methylsulfonyl group finds its significance in compounds exhibiting anti-inflammatory (Lim *et al.*, 2017), anti-allergic (Guda *et al.*, 2013), anti-bacterial, anti-fungal, and anti-cancer activity (Lad *et al.*, 2017). As a result of these, the methylsulfonyl group was included in our fabricated product with an expectation of pronounced biological activity.




Figure 1. The rationale for the development of (*E*)-1-(1-methoxy-9*H*-carbazol-3-yl)-3-(4-(methylsulfonyl)phenyl)prop-2-en-1-one

Chalcone or benzylideneacetophenone or 1,3-diphenyl-2*E*-propene-1-one is an open chain intermediate in the synthesis of aurones of the flavones pathway and subsist in numerous conjugated forms as the originator of many flavonoids and isoflavonoids compounds (Mahapatra & Bharti, 2016). They have been reported to exhibit anti-hypertensive, anti-arrhythmic, anti-obesity, anti-platelet, hypolipidemic (Mahapatra *et al.*, 2016), anti-histaminic, anti-gout, anti-ulcer, anti-inflammatory (Mahapatra *et al.*, 2017f), anti-filarial, anti-malarial, anti-tubercular, anti-fungal, anti-retroviral, anti-bacterial, anti-protozoal (Mahapatra *et al.*, 2015), anti-neoplastic, anti-oxidant, anti-angiogenic (Mahapatra *et al.*, 2015a), anti-diabetic (Mahapatra *et al.*, 2015b), etc. The methylsulfonyl containing chalcone gained prime attention on account of anti-oxidant, anti-bacterial, anti-fungal (Kamble *et al.*, 2011), anti-inflammatory, anti-nociceptive (Razmi *et al.*, 2013), and anti-cancer activity (Ismail *et al.*, 2013).

In the present research, a chalcone was fabricated rationally by incorporating a natural portion (murrayanine) in the A-ring and a synthetic component (4-methylsulfonyl group) in the B-ring and screened against two bacterial and two fungal species.

MATERIALS AND METHODS

Chemicals and Instrumentation


4'-(methylsulfonyl) acetophenone, the reactant, was purchased from Sigma Aldrich, Germany. The reagents and chemicals employed for the extraction of murrayanine and for experimental studies were of analytical grade and procured from HiMedia Ltd., India. The spectral data were obtained using the following: FT-IR study (KBr based Shimadzu[®] IRAffinity-1 instrument); ¹H-NMR study (Bruker Avance-II instrument, calibrated using the internal standard tetramethylsilane); and mass study (MICROMASS Q-TOF instrument). The progress of the reaction was detected by pre-coated TLC plates of silica gel-G (Merck, India). CHN analysis was performed on PerkinElmer 2400 model Elemental Analyzer.

Extraction of murrayanine

The starting compound murrayanine (**1**) was isolated based on our previous reports (Mahapatra *et al.*, 2017). The powdered *M. koenigii* stem bark was extracted with n-hexane employing silica gel-based column chromatography and the obtained hexane fractions (B₂₁-B₃₇) were inspected by thin layer chromatography. The product was further concentrated using the vacuum rotary evaporator.

Synthesis of target compounds

The semi-synthesis involved reaction of -CHO portion (aldehyde) of murrayanine (**1**) with the acetyl part (-COCH₃) of the methylsulfonyl containing acetophenone (**2**) in the presence of the ethanolic NaOH solution to form a benzylideneacetophenone (chalcone) scaffold (**3**) comprising of a carbonyl function (β-hydroxyketone) by aldol condensation based mechanism (Mahapatra *et al.*, 2017e). The **Scheme 1** describes the semi-synthetic route of chalcone compound.



Scheme 1. Semi-synthetic approach for the fabrication of chalcone based compound.

Synthetic protocol for (*E*)-1-(1-methoxy-9*H*-carbazol-3-yl)-3-(4-(methylsulfonyl) phenyl) prop-2-en-1-one (**3**)

In the presence of an aqueous solution of sodium hydroxide (20 mL) containing 90% ethanol (25 mL), an equal concentration (0.01 M) of murrayanine (**1**) and 4'-(methylsulfonyl) acetophenone (**2**) were reacted in reflux system for the period of 3 hr. For overnight, the reaction content was made to stand and the

mixture was added over the ice (containing a few drops of dilute HCl) with stirring to precipitate out the solid product. The obtained chalcone (**3**) was filtered, washed properly, and recrystallized suitably.

61% yield; FTIR (KBr) ν (cm^{-1}): 3199 (-NH, stretching), 3121 (C-H, aromatic), 1686 (C=O), 1619 (C=C, aromatic), 1573 (-NH, bending), 1304 (C-N), 1248 (C-O), 1056 (S=O); $^1\text{H NMR}$ (δ , ppm, CDCl_3): 10.14 (9, 1H), 7.2-8.5 (Aromatic, 10H), 3.77 (1, 3H), 3.29 (17, 3H). MS: M^+ 405. Anal. Calcd. for $\text{C}_{23}\text{H}_{19}\text{NO}_4\text{S}$: C, 68.13; H, 4.72; N, 3.45. Found: C, 67.88; H, 4.29; N, 3.14.

Anti-microbial screening

The fabricated chalcone (**3**) was screened both for anti-bacterial studies against *Escherichia coli* (*E. coli*, MTCC 2961) and *Staphylococcus aureus* (*S. aureus*, MTCC 3160), and also for anti-fungal studies against *Candida albicans* (*C. albicans*, MTCC 227) and *Aspergillus niger* (*A. niger*, MTCC 277). The study was performed by disc diffusion method against these pathogens by employing Muller Hinton Agar medium (for anti-bacterial) / Potato dextrose agar medium (for anti-fungal). Initially, the species were cultured in the nutrient broth environment followed by incubation at 37°C for 24 hr. Subsequently, the cultured microbial cells were transferred onto the specific agar plates under a laminar flow cabinet. The experimental compound was dissolved in dimethylsulfoxide (DMSO), soaked over Whatman filter paper, kept over the bacterial plates, and incubated at 37°C for 24 hrs (for anti-bacterial) / 28±2°C for 72 hrs (for anti-fungal). The anti-microbial potential was measured from the zone of inhibition diameter (in mm) using ciprofloxacin (for anti-bacterial) / fluconazole (for anti-fungal) as the positive control and DMSO as the negative control (Telrandhe *et al.*, 2017). The minimum inhibitory concentration (MIC) was determined by the agar streak dilution method which involved the preparation of microbial suspension containing 10^5 CFU/mL (approximately) and applied to the petridish with serial dilution in DMSO. The required quantity of the suspension containing the test sample was transferred at a temperature of 40-50°C into a petridish, up to 4-5 mm depth and permitted to set aside. The microbial content was incubated at 37±1°C. The MIC values were measured in triplicate manner and their average was taken. Ciprofloxacin (for anti-bacterial) / fluconazole (for anti-fungal) was employed as the positive control and DMSO as the negative control (Kamble *et al.*, 2017).

RESULTS AND DISCUSSION

Chemistry

The FT-IR spectra revealed several crucial aspects which aided in the structure determination. The vanishing of respective aldehydes peak in the spectra of the starting material murrayanine (**1**) and evolution of a new peak of the C=O at 1686 cm^{-1} in IR-spectra supported the formation of chalcone (**3**). The determined ratios of carbon, hydrogen, and nitrogen by the elemental analysis further supported the fabrication of the new compound. The $^1\text{H-NMR}$ spectra helped to obtain vital structural information. The observed range of 7.2-8.5 ppm presented the existence of 10 aromatic protons. The methyl protons of the methylsulfonyl group were chiefly noticed at 3.29 ppm, confirming the unification of the synthetic component at ring-B of the chalcone. Additionally, the protons of the methoxy group were chiefly located at 3.77 ppm. The -NH section of the murrayanine was principally seen at 10.14 ppm, thereby, further confirming the presence of natural portion in the ring-A of the chalcone. Besides the obtained data, the mass spectra finally confirmed the formation of the proposed compound due to the appearance of the base peak corresponding with the molecular weight of the chalcone (**3**). The fragment peaks (m/z 100-175) represented the fragmentation of the molecule into respective aromatic fragments.

Anti-microbial study

The formed product (**3**) expressed noteworthy anti-microbial activity. The fabricated chalcone was observed to be a better anti-bacterial agent as compared to its anti-fungal potentials. The molecule exhibited the best growth inhibition of *E. coli* as compared to *S. aureus*. The anti-fungal activity of the compound was displayed best against *A. niger* than *C. albicans* (Table 1). However, a marked difference in the inter- and intra-variability was not observed. As compared to the standard drugs, the experimental molecule does hold well against pathogenic challenges. Therefore, from this study, an anti-infective perspective was found for the novel chalcone.

CONCLUSION

The rationally designed chalcone; (*E*)-1-(1-methoxy-9*H*-carbazol-3-yl)-3-(4-(methylsulfonyl) phenyl) prop-2-en-1-one, comprising of both natural (murrayanine) and synthetic (4-methylsulfonyl) components demonstrated noteworthy anti-microbial activity. The fabricated chalcone was observed to be a better anti-bacterial agent as compared to its anti-fungal potentials. As compared to the standard drugs, the experimental molecule does hold well against pathogenic challenges. The present research, therefore, opened new avenues of judiciously developing a natural scaffold having an active methylsulfonyl group, which will inspire life science researchers across the globe in developing inhibitors with pronounced biological activity as compared with the parent compounds.

ACKNOWLEDGMENT

Authors are highly thankful to Savitribai Phule Pune University, Pune, Maharashtra, India for providing research grants (Grant No. 13PHM000126).

REFERENCES

- Guda DR, Park SJ, Lee MW, Kim TJ, Lee ME. Syntheses and anti-allergic activity of 2-((bis (trimethylsilyl) methylthio/methylsulfonyl) methyl)-5-aryl-1, 3, 4-oxadiazoles. *Eur J Med Chem* 2013;62:84-8.
- Ismail B, Ghezali L, Gueye R, Limami Y, Pouget C, Leger DY, Martin F, Beneytout JL, Duroux JL, Diab-Assaf M, Fagnere C. Novel methylsulfonyl chalcones as potential antiproliferative drugs for human prostate cancer: Involvement of the intrinsic pathway of apoptosis. *Int J Oncol* 2013;43(4):1160-8.

3. Kamble MA, Mahapatra DK, Dhabarde DM, Ingole AR. Pharmacognostic and pharmacological studies of Bombax ceiba thorn extract. *J Pharm Pharmacog Res* 2017;5(1):40-54.
4. Kamble VM, Hatnapure GD, Keche AP, Biradjar S, Patil SG, Tale RH, Rodge AH, Turkar SS, Gour K. Synthesis and Biological Evaluation of a Novel Series of Methoxylatedchalcone as Antioxidant and Anti-microbial Agents. *J Chem Pharm Res* 2011;3(6):639-48.
5. Lad NP, Manohar Y, Mascarenhas M, Pandit YB, Kulkarni MR, Sharma R, Salkar K, Suthar A, Pandit SS. Methylsulfonyl benzothiazoles (MSBT) derivatives: Search for new potential antimicrobial and anticancer agents. *Bioorg Med Chem Lett* 2017;27(5):1319-24.
6. Lim H, Kim HJ, Jeong H, Park HR. Anti-inflammatory effects of 1-isothiocyanato-7-(methylsulfonyl) heptane by suppressing the NFκ-B signaling pathway. *Eur J Inflam* 2017;15(2):57-65.
7. Mahapatra DK, Das D, Shivhare RS, Borkar SS. Murrayanine-hydantoin and -thiohydantoin analogs as promising anti-convulsant agents: Synthesis, Characterization and Molecular Docking Studies. *MOJ Bioorg Org Chem* 2018;2(2):47-51.
8. Mahapatra DK, Shivhare RS, Gupta SD. Anxiolytic activity of some 2,3-dihydrobenzo[b][1,4]oxazepine derivatives synthesized from Murrayanine-Chalcone. *Asian J Res Pharm Sci* 2018a;8(1):25-29.
9. Mahapatra DK, Shivhare RS, Asati V. Locomotor inhibitory activity of some Murrayanine-Chalcone based 2,3-dihydrobenzo[b][1,4]thiazepine derivatives: Exploring Anxiolytic potentials. *Chronicle Pharm Sci* 2018b;2(1):462-468.
10. Mahapatra DK, Shivhare RS, Ugale VG. Anti-inflammatory potentials of some novel Murrayanine containing 1,3,4-Oxadiazole derivatives. *Asian J Pharm Technol* 2018c;8(1):47-51.
11. Mahapatra DK, Shivhare RS, Kumar P. Murrayanine-chalcone transformed into novel pyrimidine compounds demonstrated promising anti-inflammatory activity. *Asian J Pharm Res* 2018d;8(1):6-10.
12. Mahapatra DK, Bharti SK, Eds. *Handbook of Research on Medicinal Chemistry*. New Jersey: Apple Academic Press, 2017.
13. Mahapatra DK, Shivhare RS, Joseph TM. Design and characterization of Murrayanine linked Isoxazole derivatives: Novel class of bacteriocidal agents. *Int J Res Drugs Pharm Sci* 2017;1(1):11-15.
14. Mahapatra DK, Shivhare RS, Bharti SK. Novel Murrayanine based Pyrazole analogs as emerging anti-fungal candidates: Design, synthesis, characterization, and in vitro evaluation. *Res Pharm* 2017a; 1(1): 1-5.
15. Mahapatra DK, Shivhare RS. Synthesizing an anti-oxidant principle 2-(((1-methoxy-9H-carbazol-3-yl)methylene)amino)isoindoline-1,3-dione from N-aminophthalimide and murrayanine. *Inventi Med Chem* 2017b;2017(4):1-3.
16. Mahapatra DK, Shivhare RS, Haldar AGM. Novel Schiff's base containing Murrayanine-1,3,4-Thiadiazole Hybrids as potential anti-inflammatory agents. *Asian J Chem Pharm Sci* 2017c;2(2):10-15.
17. Mahapatra DK, Das D, Shivhare RS. Substituted thiazole linked murrayanine-Schiff's base derivatives as potential anti-breast cancer candidates: Future EGFR Kinase inhibitors. *In J Pharm Sci Drug Res* 2017d;9(3):139-144.
18. Mahapatra DK, Chhajed SS, Shivhare RS. Development of Murrayanine-Chalcone hybrids: An effort to combine two privilege scaffolds for enhancing hypoglycemic activity. *Int J Pharm Chem Anal* 2017e;4(2):30-34.
19. Mahapatra DK, Bharti SK, Asati V. Chalcone Derivatives: Anti-inflammatory Potential and Molecular Targets Perspectives. *Curr Top Med Chem* 2017f;17(28):3146-69.
20. Mahapatra DK, Bharti SK, Asati V. Chalcone scaffolds as anti-infective agents: Structural and molecular target perspectives. *Eur J Med Chem* 2015;101:496-524.
21. Mahapatra DK, Bharti SK, Asati V. Anti-cancer chalcones: Structural and molecular target perspectives. *Eur J Med Chem* 2015a;98:69-114.
22. Mahapatra DK, Asati V, Bharti SK. Chalcones and their therapeutic targets for the management of diabetes: structural and pharmacological perspectives. *Eur J Med Chem* 2015b;92:839-65.
23. Shivhare RS, Mahapatra DK, Nair RR, Deshmukh SN. Schiff's base derivatives of murrayanine demonstrated enhanced anti-oxidant activity than its parent moiety. *Indian J Pharm Edu Res* 2016;50(3):9-15.
24. Telrandhe R, Mahapatra DK, Kamble MA. Bombax ceiba thorn extract mediated synthesis of silver nanoparticles: Evaluation of anti - Staphylococcus aureus activity. *Int J Pharm Drug Anal* 2017;5(9):376-379.

Table 1. Anti-microbial activity of the synthesized chalcone.

Compounds	<i>E. coli</i>	<i>S. aureus</i>	<i>C. albicans</i>	<i>A. niger</i>
3	24.11±0.94 (25)	26.34±1.12 (25)	20.57±1.24 (25)	21.44±0.89 (25)
Ciprofloxacin	33.73±1.76 (6.25)	31.28±1.69 (6.25)	-	-
Fluconazole	-	-	31.83±1.81 (6.25)	32.54±1.37 (6.25)

Zone of inhibition in millimeter, SD = standard deviation.

How to cite this article

Mahapatra, D. K., & Shivhare, R. S. (2018). Anti-microbial Perspective of a Chalcone, (*E*)-1-(1-methoxy-9*H*-carbazol-3-yl)-3-(4-(methylsulfonyl) phenyl)prop-2-en-1-one: Fabrication of a Hybrid by Unification of a Natural Product with a Synthetic Component. Int J Agr Life Sci, 4(2), 236-240. doi: 10.22573/spg.ijals.018.s12200090

CONFLICTS OF INTEREST

"The authors declare no conflict of interest".

© 2018 by the authors; Published by SKY FOX Publishing Group, Tamilnadu, India. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/4.0/>).